Mpex Pharmaceuticals, Inc.
http://www.mpexpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mpex Pharmaceuticals, Inc.
Korea 2024 Outlook: Continued Focus On Drug Delivery Technologies
In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.
Korea 2023 Review: R&D Potential Shines Through Despite Challenges
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.
Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
Are Korean Biopharma Alliances Recovering After Gloomy Year?
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice